Cosmos Health Announces Share Repurchase Update

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 22 hours ago

0mins

COSM-11.3%

Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

Share Repurchase Progress: Cosmos Health has repurchased an additional 230,000 shares at an average price of approximately $0.2539 per share, bringing the total repurchased shares to 3,870,000 for about $758,000, demonstrating the company's confidence in its intrinsic value.
Repurchase Program Details: The total repurchase program is set at $5 million and is expected to continue until December 31, 2026, with the option for the company to renew based on market conditions, indicating a strategic flexibility in response to market dynamics.
CEO's Confidence Statement: CEO Greg Siokas stated that the ongoing share repurchase reflects the company's belief that the market undervalues its platform strength and business trajectory, aiming to bolster investor confidence.
Global Business Expansion: Cosmos Health is solidifying its position in the global healthcare market through diversified investments in pharmaceuticals and nutraceuticals, alongside expansion efforts in Europe, Asia, and North America via its subsidiaries.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy COSM?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on COSM

About COSM

Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Cosmos Health Reports Record Q2 2026 Revenue Growth

1 day agoNewsfilter

Significant Revenue Growth: Cosmos Health anticipates Q2 2026 revenue of approximately $19.4 million, reflecting a 31.5% year-over-year increase from $14.75 million in Q2 2025, showcasing the company's strong market performance and growth potential.
Impressive First Half Performance: The company expects first-half 2026 revenue to reach approximately $37.3 million, up 31% from $28.46 million in H1 2025, marking the highest revenue in its history and further solidifying its market position.
Share Repurchase Program: As of July 6, 2026, Cosmos Health has repurchased 3,640,000 shares for approximately $700,000 under its $5 million buyback program, indicating confidence in its stock value and plans to continue repurchases as market conditions allow.
CEO Highlights Growth Momentum: CEO Greg Siokas emphasized that the company achieved record revenues in both Q2 and H1 2026 while actively repurchasing stock to enhance long-term shareholder value, demonstrating strong confidence in future growth prospects.

Cosmos Health Reports Q2 Revenue Growth and Share Buyback Update

9 hours agoNASDAQ.COM

Revenue Growth: Cosmos Health anticipates Q2 2026 revenue of approximately $19.4 million, representing a 31.5% increase from $14.75 million in Q2 2025, indicating strong market demand for its nutraceutical products.
First Half Performance: The company expects to report H1 2026 revenue of around $37.3 million, up approximately 31% from $28.46 million in the previous year, reflecting ongoing expansion in the pharmaceuticals and dietary supplements market.
Share Buyback Program: Cosmos Health has repurchased an additional 230,000 shares at an average price of about $0.2539 per share, totaling 3.87 million shares repurchased for approximately $758,000, demonstrating confidence in its stock value.
Market Performance: Despite trading between $0.16 and $1.32 over the past year, the stock closed at $0.25, down 4.89%, and further declined 2.26% in after-hours trading, reflecting cautious market sentiment regarding its short-term performance.